Longeveron is focusing on using its primary treatment, laromestrocel, to fight a rare pediatric heart birth defect that devastates families and continues to receive good FDA news regarding its treatment for Alzheimer's Disease, while also expanding its pipeline. The company announced its 3Q 2025 earnings results that showed good cost discipline, while giving a timeline for the path to commercialization. The company is at an inflection point, and we are optimistic about the direction the company will take.
